| pubmed-article:6582925 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6582925 | lifeskim:mentions | umls-concept:C0023418 | lld:lifeskim |
| pubmed-article:6582925 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:6582925 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:6582925 | lifeskim:mentions | umls-concept:C0439849 | lld:lifeskim |
| pubmed-article:6582925 | lifeskim:mentions | umls-concept:C0376152 | lld:lifeskim |
| pubmed-article:6582925 | lifeskim:mentions | umls-concept:C0080129 | lld:lifeskim |
| pubmed-article:6582925 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:6582925 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:6582925 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:6582925 | pubmed:dateCreated | 1984-4-13 | lld:pubmed |
| pubmed-article:6582925 | pubmed:abstractText | The relationship between the pretherapy cell cycle characteristics of leukaemic marrow cells and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia was studied in newly diagnosed and relapsed patients who were then treated with either combination chemotherapy consisting of cytosine arabinoside/anthracycline antibiotic +/- 6 thioguanine or with single agent high-dose cytosine arabinoside therapy. The outcome of high-dose cytosine arabinoside therapy was highly dependent upon the per cent of pretherapy cells in S phase with no remissions occurring in patients in whom the 3H-TdR labelling index was less than 6%. In contrast, the outcome of cytosine arabinoside/anthracycline antibiotic therapy was independent of the pretherapy cell cycle characteristics of the leukaemic cells. | lld:pubmed |
| pubmed-article:6582925 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6582925 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6582925 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6582925 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6582925 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6582925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6582925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6582925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6582925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6582925 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6582925 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:6582925 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:6582925 | pubmed:author | pubmed-author:MillerKK | lld:pubmed |
| pubmed-article:6582925 | pubmed:author | pubmed-author:PreislerH DHD | lld:pubmed |
| pubmed-article:6582925 | pubmed:author | pubmed-author:GoldbergJJ | lld:pubmed |
| pubmed-article:6582925 | pubmed:author | pubmed-author:BrennanJJ | lld:pubmed |
| pubmed-article:6582925 | pubmed:author | pubmed-author:RazaAA | lld:pubmed |
| pubmed-article:6582925 | pubmed:author | pubmed-author:ChervenickPP | lld:pubmed |
| pubmed-article:6582925 | pubmed:author | pubmed-author:VoglerRR | lld:pubmed |
| pubmed-article:6582925 | pubmed:author | pubmed-author:BrowmanGG | lld:pubmed |
| pubmed-article:6582925 | pubmed:author | pubmed-author:GrunwaldHH | lld:pubmed |
| pubmed-article:6582925 | pubmed:author | pubmed-author:AzarniaNN | lld:pubmed |
| pubmed-article:6582925 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6582925 | pubmed:volume | 56 | lld:pubmed |
| pubmed-article:6582925 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6582925 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:6582925 | pubmed:pagination | 399-407 | lld:pubmed |
| pubmed-article:6582925 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:6582925 | pubmed:meshHeading | pubmed-meshheading:6582925-... | lld:pubmed |
| pubmed-article:6582925 | pubmed:meshHeading | pubmed-meshheading:6582925-... | lld:pubmed |
| pubmed-article:6582925 | pubmed:meshHeading | pubmed-meshheading:6582925-... | lld:pubmed |
| pubmed-article:6582925 | pubmed:meshHeading | pubmed-meshheading:6582925-... | lld:pubmed |
| pubmed-article:6582925 | pubmed:meshHeading | pubmed-meshheading:6582925-... | lld:pubmed |
| pubmed-article:6582925 | pubmed:meshHeading | pubmed-meshheading:6582925-... | lld:pubmed |
| pubmed-article:6582925 | pubmed:meshHeading | pubmed-meshheading:6582925-... | lld:pubmed |
| pubmed-article:6582925 | pubmed:meshHeading | pubmed-meshheading:6582925-... | lld:pubmed |
| pubmed-article:6582925 | pubmed:meshHeading | pubmed-meshheading:6582925-... | lld:pubmed |
| pubmed-article:6582925 | pubmed:meshHeading | pubmed-meshheading:6582925-... | lld:pubmed |
| pubmed-article:6582925 | pubmed:meshHeading | pubmed-meshheading:6582925-... | lld:pubmed |
| pubmed-article:6582925 | pubmed:meshHeading | pubmed-meshheading:6582925-... | lld:pubmed |
| pubmed-article:6582925 | pubmed:meshHeading | pubmed-meshheading:6582925-... | lld:pubmed |
| pubmed-article:6582925 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6582925 | pubmed:articleTitle | Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia. | lld:pubmed |
| pubmed-article:6582925 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6582925 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6582925 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6582925 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6582925 | lld:pubmed |
